Arena Pharmaceuticals Reports 2003 Third Quarter and Nine Months Results
SAN DIEGO, Oct 22, 2003 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today reported revenues of $2.9 million for the quarter ended
September 30, 2003, compared to third quarter 2002 revenues of $3.0 million,
and $11.2 million in revenues for the nine months ended September 30, 2003,
compared to $13.1 million in revenues for the nine months ended September 30,
2002. Arena earns revenues under its collaborations primarily from research
funding, milestone payments, and technology access and development fees.
Arena reported a net loss for the third quarter and first nine months of 2003
of $11.9 million, or $.43 per share, and $32.4 million, or $1.17 per share,
respectively. This compares with a net loss for the third quarter and first
nine months of 2002 of $10.3 million, or $.37 per share, and $24.1 million, or
$.88 per share, respectively.
Research and development expenses totaled $12.6 million in the third
quarter of 2003, compared to $12.0 million in the third quarter of 2002. In
the nine months ended September 30, 2003, research and development expenses
totaled $37.8 million, compared to $31.1 million in the nine months ended
September 30, 2002. General and administrative expenses totaled $2.1 million
in the third quarter of 2003, compared to $1.8 million in the third quarter of
2002. In the nine months ended September 30, 2003, general and administrative
expenses totaled $6.0 million, compared to $5.5 million in the nine months
ended September 30, 2002.
Cash, cash equivalents and short-term investments totaled $146.0 million
at September 30, 2003. Total shares outstanding were 28.6 million at
September 30, 2003.
"This past quarter we completed the major portion of our preclinical
testing for our obesity product, APD356, and made significant advances in the
sleep, diabetes, cardiovascular and inflammation areas," stated Jack Lief,
President and CEO of Arena. "I am pleased with our significant progress
toward moving our R&D programs forward while maintaining overall spending
comparable to last year."
Subsequent to the third quarter of 2003, Arena announced that
Biotechnology Value Fund, L.P. and certain of its affiliates accepted Arena's
offer to purchase three million shares of Arena common stock from them at a
cash price per share of $7.69. Arena made the offer on October 7, 2003,
pursuant to the Stockholders Agreement dated as of January 17, 2003, by and
among Arena and Biotechnology Value Fund, L.P., Biotechnology Value Fund II,
L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. and Investment 10,
L.L.C. Arena paid cash of $23.1 million for this purchase.
Arena is a biopharmaceutical company focused on discovering and developing
drugs that act on an important class of drug targets called G protein-coupled
receptors, or GPCRs. Arena uses its Constitutively Activated Receptor
Technology, or CART, Melanophore technology and other proprietary
technologies to better understand GPCRs and to identify small molecules that
may lead to new drugs. Arena focuses its efforts in four therapeutic areas:
metabolic diseases, cardiovascular diseases, central nervous system disorders
and inflammatory diseases. Within these areas, Arena is developing a
portfolio of internally discovered, highly selective small molecules for large
markets with unmet medical needs, including obesity, diabetes, depression and
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's strategy, technologies, internal
programs, future achievements, and statements that are not historical facts,
including statements about Arena's ability to identify and develop small
molecules or which are preceded by the word "will" or similar words. For such
statements, Arena claims the protection of the Private Securities Litigation
Reform Act of 1995. Actual events or results may differ materially from
Arena's expectations. Important factors that could cause actual results to
differ materially from those stated or implied by Arena's forward-looking
statements are disclosed in Arena's SEC reports, including Arena's most recent
quarterly report on Form 10-Q. These forward-looking statements represent
Arena's judgment as of the date of this release. Arena disclaims any intent
or obligation to update these forward-looking statements.
Arena Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
Three months ended Nine months ended
September 30, September 30,
2003 2002 2003 2002
revenues $2,868,675 $2,987,741 $11,217,885 $13,057,541
development 12,565,001 12,001,252 37,762,310 31,138,313
administrative 2,059,818 1,842,302 6,026,989 5,463,786
compensation 692,141 463,931 2,554,791 1,820,412
technology 405,305 405,305 1,215,915 1,180,822
expenses 15,722,265 14,712,790 47,560,005 39,603,333
income, net 977,955 1,543,823 3,892,735 4,281,194
writedown -- (86,797) -- (1,786,797)
Net loss $(11,875,635) $(10,268,023) $(32,449,385) $(24,051,395)
Net loss per
and diluted $(0.43) $(0.37) $(1.17) $(0.88)
net loss per
and diluted 27,764,676 27,514,085 27,725,907 27,464,983
Condensed Consolidated Balance Sheet Data
September 30, December 31,
Cash, cash equivalents and
short-term investments $146,027,914 $185,142,885
Other current assets 5,128,713 8,166,767
Land, property and equipment, net 55,025,979 44,073,365
Acquired technology, investments
and other assets 14,137,305 17,507,030
Total assets $220,319,911 $254,890,047
Liabilities and Stockholders' Equity
Liabilities $9,298,153 $12,838,346
Stockholders' equity 211,021,758 242,051,701
Total liabilities and
stockholders' equity $220,319,911 $254,890,047
Note: The Condensed Consolidated Balance Sheet Data at December 31, 2002,
has been derived from the audited financial statements as of that date.
Arena Pharmaceuticals® and Arena® are registered service marks of the
company. CART is an unregistered service mark of the company. Arena's
headquarters are at 6166 Nancy Ridge Drive, San Diego, CA 92121, and its
telephone number is (858) 453-7200. On the Internet, please refer to Arena's
website: www.arenapharm.com for further information.
Arena will be hosting both a telephone and live Internet second quarter
2003 conference call on Wednesday October 22, 2003, at 5:00 p.m. Eastern Time
(2:00 p.m. San Diego Time).
Jack Lief, President and Chief Executive Officer, and Joseph Mooney, Chief
Financial Officer, will discuss the third quarter results, the progress of
Arena's collaborations and other topics. A Question and Answer session will
follow the presentation. To access by telephone, dial in toll free at
(888) 273-9887 (the international dial in number is (612) 332-0345), and
specify that you would like to join the "Third Quarter Earnings Conference
Call." To access the call via the Internet, go to www.arenapharm.com and
click on "Investor Relations." Then, click on "Calendar of Events." The
conference call will be listed at the top of the page. Click on the "Live
Webcast" link. Then, follow the links and instructions provided. Listening
to the conference call on the Internet will require speakers and Microsoft
Windows Media Player. An archive of the webcast will be available on Arena's
website until October 29, 2003.
SOURCE Arena Pharmaceuticals, Inc.
Jack Lief, President & CEO, +1-858-453-7200 ext. 223, or Joseph
Mooney, CFO, +1-858-453-7200 ext. 508, both of Arena Pharmaceuticals, Inc.